“The liver cirrhosis treatment market is poised for significant growth, driven by the rising global prevalence of liver diseases, particularly NAFLD, fueled by lifestyle factors like obesity, alcohol consumption, and metabolic syndrome. Technological advancements in antiviral therapies and regenerative medicine are enhancing treatment outcomes, while an aging population further increases demand. These factors collectively highlight a strong growth trajectory for the market.”
DelveInsight’s January 2025 report highlights significant momentum in the liver cirrhosis clinical trial pipeline, with over 30 companies actively developing more than 30 investigational therapies. This surge is driven by the increasing global prevalence of liver diseases, particularly non-alcoholic fatty liver disease (NAFLD), influenced by lifestyle factors such as obesity, alcohol consumption, and metabolic syndrome. Advancements in antiviral therapies and regenerative medicine, coupled with an aging population, are further propelling market growth. SOURCE:
Key Highlights:
- Leading Companies: Notable pharmaceutical and biotech firms engaged in developing liver cirrhosis treatments include Versantis AG, Mirum Pharmaceuticals, Sagimet Biosciences, TenNor Therapeutics, Prism Pharma, Vedanta Biosciences, Lipocine, Gwo Xi Stem Cell Applied Technology, Galectin Therapeutics, Resolution Therapeutics, Ipsen, and AstraZeneca.
- Promising Therapies: Several investigational drugs are in various stages of clinical development, such as Volixibat, VS-01, TVB-2640, TNP-2092, PRI-724, VE303, LPCN 1148, GXHPC1, Belapectin, RTX001, Elafibranor, and Zibotentan.
- Recent Clinical Developments:
- December 2024: Galectin Therapeutics announced results from its global NAVIGATE trial evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
- October 2024: PharmaIN Corporation presented interim results from its ongoing Phase I trial of PHIN-214, aimed at preventing and treating decompensated cirrhosis.
- June 2024: Resolution Therapeutics, in collaboration with the University of Edinburgh, showcased data on RTX001 at the EASL Congress, demonstrating the potential of macrophage cell therapy for advanced liver cirrhosis.
- June 2024: Lipocine’s Phase II results on LPCN 1148 were featured in a late-breaking oral presentation at the EASL Congress.
- April 2024: LyGenesis dosed the first patient in its Phase IIa trial evaluating an allogenic regenerative cell therapy transplanted into lymph nodes as a potential treatment for end-stage liver disease.
- March 2024: Lipocine announced positive topline results from a Phase II study of LPCN 1148 for managing liver cirrhosis.
The report provides comprehensive profiles of these pipeline assets, comparative analyses of clinical and non-clinical stage drugs, assessments of inactive and dormant assets, and evaluations of market drivers, barriers, opportunities, and risks within the liver cirrhosis clinical trial landscape.